Primary Progressive Multiple Sclerosis Treatment Market (Drug Type: Approved Drugs & Pipeline Drugs; & Distribution Channel: Retail Pharmacies, E-commerce, & Others) - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2022-2031

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Primary Progressive Multiple Sclerosis Treatment Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, 2017 - 2031
  • 4.4.1. Market Revenue Projections (US$ Mn)
• 4.5. Porter's Five Force Analysis

5. Key Insights

• 5.1. Key Mergers & Acquisitions
• 5.2. Pipeline Analysis
• 5.3. Disease Prevalence & Incidence Rate globally with key countries
• 5.4. Key Product/Brand Analysis
• 5.5. Major Research Institutes Involved
• 5.6. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Drug Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Drug Type, 2017 - 2031
  • 6.3.1. Approved Drugs
  • 6.3.2. Pipeline Drugs
• 6.4. Market Attractiveness By Drug Type

7. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Distribution Channel

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast By Distribution Channel, 2017 - 2031
  • 7.3.1. Retail Pharmacies
  • 7.3.2. E-commerce
  • 7.3.3. Others
• 7.4. Market Attractiveness By Distribution Channel

8. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Region

• 8.1. Key Findings
• 8.2. Market Value Forecast By Region
  • 8.2.1. North America
  • 8.2.2. Europe
  • 8.2.3. Asia Pacific
  • 8.2.4. Latin America
  • 8.2.5. Middle East & Africa
• 8.3. Market Attractiveness By Country/Region

9. North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

• 9.1. Introduction
  • 9.1.1. Key Findings
• 9.2. Market Value Forecast By Drug Type, 2017 - 2031
  • 9.2.1. Approved Drugs
  • 9.2.2. Pipeline Drugs
• 9.3. Market Value Forecast By Distribution Channel, 2017 - 2031
  • 9.3.1. Retail Pharmacies
  • 9.3.2. E-commerce
  • 9.3.3. Others
• 9.4. Market Value Forecast By Country, 2017 - 2031
  • 9.4.1. U.S.
  • 9.4.2. Canada
• 9.5. Market Attractiveness Analysis
  • 9.5.1. By Drug Type
  • 9.5.2. By Distribution Channel
  • 9.5.3. By Country

10. Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Drug Type, 2017 - 2031
  • 10.2.1. Approved Drugs
  • 10.2.2. Pipeline Drugs
• 10.3. Market Value Forecast By Distribution Channel, 2017 - 2031
  • 10.3.1. Retail Pharmacies
  • 10.3.2. E-commerce
  • 10.3.3. Others
• 10.4. Market Value Forecast By Country, 2017 - 2031
  • 10.4.1. Germany
  • 10.4.2. U.K.
  • 10.4.3. France
  • 10.4.4. Spain
  • 10.4.5. Italy
  • 10.4.6. Rest of Europe
• 10.5. Market Attractiveness Analysis
  • 10.5.1. By Drug Type
  • 10.5.2. By Distribution Channel
  • 10.5.3. By Country

11. Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Drug Type, 2017 - 2031
  • 11.2.1. Approved Drugs
  • 11.2.2. Pipeline Drugs
• 11.3. Market Value Forecast By Distribution Channel, 2017 - 2031
  • 11.3.1. Retail Pharmacies
  • 11.3.2. E-commerce
  • 11.3.3. Others
• 11.4. Market Value Forecast By Country, 2017 - 2031
  • 11.4.1. China
  • 11.4.2. Japan
  • 11.4.3. India
  • 11.4.4. Australia & New Zealand
  • 11.4.5. Rest of Asia Pacific
• 11.5. Market Attractiveness Analysis
  • 11.5.1. By Drug Type
  • 11.5.2. By Distribution Channel
  • 11.5.3. By Country

12. Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Drug Type, 2017 - 2031
  • 12.2.1. Approved Drugs
  • 12.2.2. Pipeline Drugs
• 12.3. Market Value Forecast By Distribution Channel, 2017 - 2031
  • 12.3.1. Retail Pharmacies
  • 12.3.2. E-commerce
  • 12.3.3. Others
• 12.4. Market Value Forecast By Country, 2017 - 2031
  • 12.4.1. Brazil
  • 12.4.2. Mexico
  • 12.4.3. Rest of Latin America
• 12.5. Market Attractiveness Analysis
  • 12.5.1. By Drug Type
  • 12.5.2. By Distribution Channel
  • 12.5.3. By Country

13. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Drug Type, 2017 - 2031
  • 13.2.1. Approved Drugs
  • 13.2.2. Pipeline Drugs
• 13.3. Market Value Forecast By Distribution Channel, 2017 - 2031
  • 13.3.1. Retail Pharmacies
  • 13.3.2. E-commerce
  • 13.3.3. Others
• 13.4. Market Value Forecast By Country, 2017 - 2031
  • 13.4.1. GCC Countries
  • 13.4.2. South Africa
  • 13.4.3. Rest of Middle East & Africa
• 13.5. Market Attractiveness Analysis
  • 13.5.1. By Drug Type
  • 13.5.2. By Distribution Channel
  • 13.5.3. By Country

14. Competition Landscape

• 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 14.2. Market Share Analysis By Company (2021)
• 14.3. Company Profiles
  • 14.3.1. F. Hoffmann-La Roche Ltd.
    • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.1.2. Company Financials
    • 14.3.1.3. Growth Strategies
    • 14.3.1.4. SWOT Analysis
  • 14.3.2. Sanofi
    • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.2.2. Company Financials
    • 14.3.2.3. Growth Strategies
    • 14.3.2.4. SWOT Analysis
  • 14.3.3. Mapi Pharma Ltd.
    • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.3.2. Company Financials
    • 14.3.3.3. Growth Strategies
    • 14.3.3.4. SWOT Analysis
  • 14.3.4. Atara Biotherapeutics
    • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.4.2. Company Financials
    • 14.3.4.3. Growth Strategies
    • 14.3.4.4. SWOT Analysis
  • 14.3.5. Takeda Pharmaceuticals International, Inc.
    • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.5.2. Company Financials
    • 14.3.5.3. Growth Strategies
    • 14.3.5.4. SWOT Analysis
  • 14.3.6. AB Science
    • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.6.2. Company Financials
    • 14.3.6.3. Growth Strategies
    • 14.3.6.4. SWOT Analysis
  • 14.3.7. Mallinckrodt
    • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.7.2. Company Financials
    • 14.3.7.3. Growth Strategies
    • 14.3.7.4. SWOT Analysis

List of Tables

• Table 01: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
• Table 02: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 03: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
• Table 04: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
• Table 05: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 06: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
• Table 07: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
• Table 08: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 09: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 10: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
• Table 11: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 12: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 13: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
• Table 14: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 15: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 16: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
• Table 17: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 18: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

• Figure 01: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
• Figure 02: Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
• Figure 03: Global Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
• Figure 04: Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
• Figure 05: Global Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
• Figure 06: Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Region, 2021 and 2031
• Figure 07: Global Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Region, 2022-2031
• Figure 08: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
• Figure 09: North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
• Figure 10: North America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
• Figure 11: North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
• Figure 12: North America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
• Figure 13: North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country, 2021 and 2031
• Figure 14: North America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country, 2022-2031
• Figure 15: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
• Figure 16: Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
• Figure 17: Europe Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
• Figure 18: Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
• Figure 19: Europe Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
• Figure 20: Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
• Figure 21: Europe Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 22: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
• Figure 23: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
• Figure 24: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
• Figure 25: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
• Figure 26: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
• Figure 27: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
• Figure 28: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 29: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
• Figure 30: Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
• Figure 31: Latin America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
• Figure 32: Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
• Figure 33: Latin America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
• Figure 34: Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
• Figure 35: Latin America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 36: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
• Figure 37: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
• Figure 38: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
• Figure 39: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
• Figure 40: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
• Figure 41: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
• Figure 42: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 43: Global Primary Progressive Multiple Sclerosis Treatment Market Share Analysis/Ranking, by Company, 2021